Clinical characteristics and response to therapeutic plasma exchange in patients diagnosed with Guillain Barré syndrome in a third level clinic in the city of Cali - Colombia during the years 2016-2022.

Clinical characteristics and response to therapeutic plasma exchange in patients diagnosed with Guillain Barré syndrome in a third level clinic in the city of Cali - Colombia during the years 2016-2022.

Main Article Content

Diego Gerardo Prado- Molina
Esteban Agudelo-Quintero
José Mauricio Cárdenas-Prieto
Juan Santiago Serna Trejos
Stefanya Geraldine Bermúdez – Moyano
Isabella Vernaza-Gutiérrez
Luis Felipe Cortez-Sanabria
Catherine Caceres-Campo

Abstract

Abstract
Introduction: Guillain Barré syndrome (GBS) presents a non-negligible incidence rate in low-income countries. Intravenous human immunoglobulin (IVIG) and therapeutic plasma exchange (TPR) are the first-line treatments. Aim: The aim of this work is to describe the clinical characteristics and the response to RPT in patients with GBS. Materials and methods: Observational, descriptive, cross-sectional study with analytical scope of patients diagnosed with GBS who were managed with RPT, in two service-providing institutions (IPS) in the city of Cali-Colombia, between 2016 and 2022. outcomes: 33 patients with a mean age of 57+/-16 years were included. After a median stay of 10 days in the intensive care unit (ICU), 75.5% decreased at least one grade on the Hughes scale, 12.1% required mechanical ventilation (MV), 27.3% presented some complication, and there were no fatal outcomes. Prolonged stay in the ICU was significantly associated with an unfavorable clinical evolution. Conclusion: The results suggest that RPT management in an institution with highly complex standards, with early diagnosis and early medical intervention, can contribute to an adequate clinical evolution. Prolonged time in the intensive care unit (ICU) is a prognostic factor to consider in the clinical evolution of these patients. Studies with an analytical design and a larger sample are required to support these findings.
Keywords
Guillain-Barré syndrome, plasma exchange, clinical evolution, intravenous immunoglobulin, early diagnosis, early medical intervention.

References

Ansar V, Valadi N. Guillain-Barré Syndrome. Primary Care: Clinics in Office Practice, vol. 42, no. 2. Jun.2015, pp.189+ https://doi.org/10.1016/j.pop.2015.01.001

Aschner P. Epidemiología de la diabetes en Colombia. Avances en Diabetología, vol. 26, no. 2, Apr.2010, pp.95+ https://doi.org/10.1016/S1134-3230(10)62005-4

Bobati SS, Naik KR. Therapeutic plasma exchange - An emerging treatment modality in patients with neurologic and non-neurologic diseases. Journal of Clinical and Diagnostic Research, vol. 11, no. 8, Aug.2017, pp.35-37 https://doi.org/10.7860/JCDR/2017/27073.10480

Donofrio PD. Guillain-Barré Syndrome. CONTINUUM American Academy of Neurology. Vol. 23, no. 5, oct.2017, pp.1295+ https://doi.org/10.1212/CON.0000000000000513

Esposito S, Longo MR. Guillain–Barré syndrome. Autoimmun Rev, vol. 16, no. 1, Sep.2016, pp.96+ https://doi.org/10.1016/j.autrev.2016.09.022

Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of GuillainBarré syndrome and validation of Brighton criteria. Brain, vol. 137. No. 1, oct. 2014, pp.33+ https://doi.org/10.1093/brain/awt285

Benitéz CG, Andresen M, Farías G, Castillo C, Henriquez M, Pereira J. Uso de plasmaféresis en unidades de pacientes. Rev Méd Chile, vol. 133, no. 1 , Oct. 2004, pp.1441+ https://www.scielo.cl/pdf/rmc/v133n12/art05.pdf

García-Peña A, Ospina D, Rico J, Fernández-Ávila DG, Muñoz-Velandia Ó, Suárez-Obando F. Prevalencia de hipertensión arterial en Colombia según información del Sistema Integral de Información de la Protección Social (SISPRO). Rev Col Cardiol, vol. 29, no.1, Jan.2022. https://doi.org/10.24875/RCCAR.M22000114

González GM, Bahamon GG, Motta AG, Ramirez CF. Síndrome Guillain-Barré: Un mirada actual. Revista Facultad de Salud, vol. 2, no 2, Jul.2016, pp.38+ https://doi.org/10.1186/s12974-021-02301-0.

Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews. Vol. 4, Jan. 2008, pp.1-22. https://doi.org/10.1002/14651858.CD001798

Córdoba JP, Larrarte C, Rondón MA. Plasmaféresis terapéutica. Act Med Col, vol 39, no. 1, Jan.2014, pp.29+ https://doi.org/10.22265/acnef.2.1.199

Kwan J, Biliciler S. Guillain-Barré Syndrome and Other Acute Polyneuropathies. Clin Geriatr Med, vol. 31, no. 2, 2021, pp.313+ https://doi.org/10.1016/j.cger.2021.01.005

Maheshwari A, Sharma R, Prinja S, Hans R, Modi M, Sharma N, et al. Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin. J Clin Apher, Jun.2018, pp.1–7. https://doi.org/10.1002/jca.21646

McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide: A systematic literature review. Neuroepidemiology, vol. 32, no. 2, Sep.2008, pp.150+.https://doi.org/10.1159/000184748

Palma-Garcia L, Velásquez-Rimachi V, Pezo-Pezo A, Roig J, Perez-Villegas J. Therapeutic plasma exchange: Experience in a third level hospital. J Clin Apher, vol. 33, no. 4, Nov. 2017, pp.480+. https://doi.org/10.1002/jca.21623

Phillips Morales Ó. Actualización en el Síndrome de Guillain-Barré. Revista Medica Sinergia, vol. 4, No. 11, Oct.2019, pp.e290+. https://doi.org/10.31434/rms.v4i11.290

Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome (Review). Cochrane Database of Systematic Reviews, vol. 7, no. 4. 2012, pp.1-47 https://doi.org/10.1002/14651858.CD001798

Rodriguez-Casero MV, Shield LK, Kornberg AJ. Subacute inflammatory demyelinating polyneuropathy in children. Neurology. Vol 64, no. 10, Feb. 2005, pp.1786+. https://doi.org/10.1212/01.WNL.0000162047.89440.B9

Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. The Lancet, vol. 397. Feb. 2021, pp.1214+. https://doi.org/10.1016/S0140-6736(21)00517-1

Suárez FE, Ortiz GI, Mogollón JP, Clavijo L, Ortíz PA, Rodríguez JH, et al. Minimización de costos: inmunoglobulina IV vs. plasmaféresis en síndrome de Guillain Barré. Act Neurol Col, vol. 32, no. 3, Aug.2016, pp.184+. http://www.scielo.org.co/scielo.phpscript=sci_arttext&pid=S0120-87482016000300002&lng=en&nrm=iso

Sudulagunta SR, Sodalagunta MB, Sepehrar M, Khorram H, Raja SK, Kothandapani S, et al. Guillain-Barré syndrome: clinical profile and management. Ger Med Sci, vol. 13, no. 16, Sep.2015. https://doi.org/10.3205/000220

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet, vol 388, Feb. 2016, pp.717+ https://doi.org/10.1016/S0140-6736(16)00339-1